Axumin Pet Scan For Prostate Cancer

The bone scan did not reveal any suspicious bony metastasis.

Axumin pet scan for prostate cancer. Axumin is an fda approved medicare covered scan that can achieve early detection of recurrent prostate cancer after surgery or radiation. It is the first fda approved f 18 labeled pet scan agent indicated in patients with suspected recurrent prostate. Axumin is a novel molecular imaging agent indicated for use in pet imaging to identify suspected sites of prostate cancer recurrence in men who have elevated blood levels of prostate specific antigen psa following prior treatment. For years we have been able to detect prostate cancer recurrences with psa but standard body and bone scans have been unable to determine the location of the cancer until the psa level is excessively elevated 10 to 30 or higher.

For years we have been able to detect prostate cancer recurrences with psa but standard body and bone scans have been unable to determine the location of the cancer until the psa level is excessively elevated 10 to 30 or higher. Axumin a 18 f fluciclovine injection is a molecular agent used in positron emission tomography pet imaging in men with suspected recurrent prostate cancer. Axumin based pet ct scans and detection of recurrent prostate cancer posted on april 30 2020 by sitemaster a new report from a relatively small single institution study has provided additional information about the utility of 18 f fluciclovine axumin pet ct scans in the detection of recurrent prostate cancer after definitive first line treatment. Axumin pet showed mild activity suvmax 1 5 in the prostate bed but not significantly higher than the blood pool activity suvmax 1 4 thus not suspicious for recurrence at the prostatic bed per the guideline.

Axumin is indicated for positron emission tomography pet imaging in men with suspected prostate cancer recurrence based on elevated psa levels following prior treatment. Axumin is an fda approved medicare covered scan that can achieve early detection of recurrent prostate cancer after surgery or radiation. Conventional ct and nuclear medicine bone scans have limited sensitivity especially in patients with low psa levels less than 10 ng ml. Thereafter the patient was referred to our center for axumin pet scan.

Axumin fluciclovine f 18 injection is a diagnostic imaging agent sometimes called a radiotracer. Axumin is used along with a positron emission tomography pet imaging scan for men who have had prior treatment for prostate cancer and now have prostate specific antigen psa levels that are elevated. For some men with prostate cancer results from a large clinical trial suggest that there may be a more effective imaging approach to detect the spread of their cancer to other parts of the body than the approach that is most commonly used. Conducted in australia the trial included men diagnosed with localized prostate cancer that was thought to be at high risk of spreading beyond the prostate.